Chromosomal Instability clinical trials at UCLA

1 research study open to eligible people

Sovilnesib in Subjects with Ovarian Cancer
open to eligible females ages 18 years and up
This is a randomized, phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of sovilnesib at different dose levels to establish the Recommended Phase 2 Dose (RP2D) of sovilnesib in subjects with high grade serous ovarian cancer (HGSOC).
Los Angeles, California and other locations

Last updated: November 5, 2024